6533b7d0fe1ef96bd125a2bc
RESEARCH PRODUCT
false
subject
0301 basic medicineGeneticsTranscription activator-like effector nucleaseNuclease030102 biochemistry & molecular biologyCas9Pcr cloningBiology3. Good health03 medical and health sciencesgenomic DNA030104 developmental biologyPlasmidProof of conceptGeneticsbiology.proteinMolecular MedicineCRISPRMolecular Biologydescription
Despite rapid progress, many problems and limitations persist and limit the applicability of gene-editing techniques. Making use of meganucleases, TALENs, or CRISPR/Cas9-based tools requires an initial step of pre-screening to determine the efficiency and specificity of the designed tools. This step remains time consuming and material consuming. Here we propose a simple, cheap, reliable, time-saving, and highly sensitive method to evaluate a given gene-editing tool based on its capacity to induce chromosomal translocations when combined with a reference engineered nuclease. In the proposed technique, designated engineered nuclease-induced translocations (ENIT), a plasmid coding for the DNA-editing tool to be tested is co-transfected into carefully chosen target cells along with that for an engineered nuclease of known specificity and efficiency. If the new enzyme efficiently cuts within the desired region, then specific chromosomal translocations will be generated between the two targeted genomic regions and be readily detectable by a one-step PCR or qPCR assay. The PCR product thus obtained can be directly sequenced, thereby determining the exact position of the double-strand breaks induced by the gene-editing tools. As a proof of concept, ENIT was successfully tested in different cell types and with different meganucleases, TALENs, and CRISPR/Cas9-based editing tools.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-06-01 | Molecular Therapy - Methods & Clinical Development |